Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.66 |
| ▸ | CTSL | P07711 | 2/20 | 0.60 |
| ▸ | CTSS | P25774 | 1/20 | 0.60 |
| ▸ | CTSK | P43235 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | ACE | P12821 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5246183 | 1.00 | TACR1 (0.66) | TACR1CTSLCTSSCTSKKMT2A | |
| SCHEMBL5246171 | 1.00 | TACR1 (0.66) | TACR1CTSLCTSSCTSKKMT2A | |
| SCHEMBL10174744 | 0.91 | ACE (0.70) | TACR1CTSLCTSSCTSKMAPT | |
| SCHEMBL5253098 | 0.91 | ACE (0.70) | TACR1CTSLCTSSCTSKMAPT | |
| SCHEMBL5253093 | 0.91 | ACE (0.70) | TACR1CTSLCTSSCTSKMAPT | |
| SCHEMBL5251038 | 0.91 | TACR1 (0.78) | TACR1CTSLCTSSCTSKKMT2A | |
| SCHEMBL621684 | 0.91 | TACR1 (0.78) | TACR1CTSLCTSSCTSKKMT2A | |
| SCHEMBL1486155 | 0.91 | TACR1 (0.78) | TACR1CTSLCTSSCTSKKMT2A | |
| SCHEMBL29400174 | 0.91 | TACR1 (0.78) | TACR1CTSLCTSSCTSKKMT2A | |
| SCHEMBL20829903 | 0.87 | TACR1 (0.72) | TACR1CTSLCTSSCTSKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382193-B2 | Processes for forming amide bonds and compositions related thereto | EMORY UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150315129-A1 | PROCESSES FOR FORMING AMIDE BONDS AND COMPOSITIONS RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| US-8921599-B2 | Processes for forming amide bonds and compositions related thereto | EMORY UNIVERSITY (US) | 2014-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315129-A1 | PROCESSES FOR FORMING AMIDE BONDS AND COMPOSITIONS RELATED THERETO | TMT1A, LPO, GSTO1 | TACR1 1746/4885CTSL 2981/4885CTSS 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.